A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2013

At a glance

  • Drugs TZP 102 (Primary)
  • Indications Diabetic gastroparesis
  • Focus Therapeutic Use
  • Acronyms DIGEST
  • Most Recent Events

    • 17 Dec 2012 Status changed from recruiting to discontinued, as reported in a Tranzyme Pharma media release.
    • 15 Nov 2012 Top line results for DIGEST are anticipated in the first half of 2013, according to a Tranzyme Pharma media release.
    • 25 Aug 2012 New source identified and integrated (European Clinical Trials Database, EudraCT2012-002576-14).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top